Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.
about
Clinical immunologic approaches for the treatment of Alzheimer's diseaseIntravenous immunoglobulin for Alzheimer's disease8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's diseaseActive and passive immunotherapy for neurodegenerative disordersThe immunotherapy of Alzheimer's diseaseAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsHerpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's DiseaseNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsIntravenous immunoglobulin and Alzheimer's disease: what now?Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease.IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathologyAmyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodiesCellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment.Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chainsChronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination toolAnti-amyloidogenic activity of IgGs contained in normal plasmaAmyloid-beta immunotherapy for Alzheimer's diseaseDrug development for Alzheimer's disease: where are we now and where are we headed?Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Immunogenic properties of amyloid beta oligomers.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.BapineuzumabAmyloid-ß-directed immunotherapy for Alzheimer's disease.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapiesInterleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsAmyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysisLong-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseaseAnti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.Autoreactive-Aβ antibodies promote APP β-secretase processing.Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.The immune system, amyloid-beta peptide, and Alzheimer's disease.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Immunization therapy in Alzheimer's disease.
P2860
Q22241380-B9DF9E2A-4444-4657-96E5-0C121C95AF33Q24188215-94FBAF34-41A8-4366-8541-14D48EDDF1E3Q24606651-2582C41A-9E68-4F9C-B35D-7467F44F8A09Q24657879-C66025B4-9966-4AE4-8A18-A77C3BA5C99EQ24804900-541FD091-EB15-42DC-89B6-21194730935AQ26740418-0DEFA06D-B8BC-4B80-AA93-C293537FA553Q26781578-D90C9F55-6AB8-40F6-B7E2-79EB85D103F0Q26866006-BBDC1AB2-2324-43BB-9162-50A2E8F538ACQ27000371-6862C1F7-2943-4775-9AFA-0C08144E1D7DQ27311810-87EFF46A-B976-455A-9758-F3C17387B9E6Q27497796-47C237CE-7429-4446-A52E-34BE9D24E43EQ28748498-E10DF2F5-DFAB-4EE2-8F49-B9B4E8F80208Q30439617-3006400D-2B22-41F3-8D36-6A9107ADC464Q33381465-A9AC8537-A2BB-4F70-860B-F80B0CCE1350Q33392254-1AB8791B-204E-4E23-84D6-8E9B18E6AE0CQ33569608-970AA8F4-EC18-40A0-AE5F-691FA6876C75Q33886377-87F20850-50BA-4470-9739-7F86F79431B7Q33903503-5508BCE6-5F72-40C4-88F6-F7E56542DDD1Q33954737-AD9AE398-09FB-467D-9EBE-E7D1BFFCF0E8Q34166256-2CDC96C5-4C3E-4E39-8B23-49CB53FC243AQ34222721-1C4163FF-328B-4339-AC1C-0CC35D37C8CCQ34329254-07083C19-23BE-449C-A9C5-145EA680C024Q34376103-467C8355-C9D4-4DB4-8E42-07984E5549C3Q34398107-91984044-4447-49F4-907C-999D0A0C4E74Q34548700-8DC15F4B-0EDA-4CF9-9A10-EE9779D2E714Q34733689-2D800F25-9615-4DB0-AFE8-A32CCC33B71FQ34974167-5A2A28AE-40EF-4119-905B-7F4E812DF943Q35015949-CF954895-53DA-4F97-9908-B59DBD622F50Q35184148-D017AAF0-D63A-4330-BF09-C8DC5254D887Q35222076-5DCC84AF-3ACC-46EB-BFAE-2CE9BC62DD99Q35540628-F9DE39B0-DD67-43D5-8CD4-9D5288356A43Q35590968-E82E7782-393D-410D-9081-3B33653575A2Q35753932-56669590-0B02-42AA-8ACD-B7FDA12A334CQ35754467-4F5D36CD-6C3D-4699-BE46-ACC785DDDF5CQ35855587-FA621AAC-3D82-466D-84B8-738C87355635Q36121068-E078B063-68B6-4E09-B295-24ED0B9843D3Q36156604-D0BAEBF4-EDBF-4285-8103-DEB0627CAB0EQ36342218-441ABC65-6A7E-48D8-9700-87757D93FF7AQ36401406-50D9A54A-CD16-4EDE-AFF0-EF353F062170Q36492332-6634A7E1-5A0B-431A-9D67-BA7F2758D7E4
P2860
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@ast
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@en
type
label
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@ast
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@en
prefLabel
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@ast
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@en
P2093
P356
P1476
Intravenous immunoglobulins co ...... atment of Alzheimer's disease.
@en
P2093
Brettschneider S
Depboylu C
Hemmeter U
P304
P356
10.1136/JNNP.2003.033399
P407
P577
2004-10-01T00:00:00Z